EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Salvage Chemotherapy After Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Chihiro Fushimi, Isaku Okamoto, Takashi Matsuki, Takuro Okada, Yuri Ueda, Hideaki Takahashi, Hiroki Sato, Takahito Kondo, Kunihiko Tokashiki, Kenji Hanyu, Tatsuya Ito, Yukiomi Kushihashi und 6 weitere

In Vivo · 2026-11 · 40 (6) · 3648-3656

DOI: 10.21873/invivo.14503 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift In Vivo, online erschienen am 29.10.2026. Verfasst von Chihiro Fushimi und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan; chfushim@ncc.go.jp. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Salvage Therapy, Squamous Cell Carcinoma of Head and Neck, Neoplasm Recurrence, Local. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedSalvage TherapySquamous Cell Carcinoma of Head and NeckNeoplasm Recurrence, LocalAntineoplastic Agents, ImmunologicalHead and Neck NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleMiddle AgedAgedNeoplasm MetastasisRetrospective StudiesTreatment OutcomeAdult

Stichwörter der Autor:innen

Pembrolizumabcetuximabhead and neck cancerpaclitaxelrecurrent/metastaticsalvage chemotherapy

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan; chfushim@ncc.go.jp.
  • Department of Head and Neck Surgery, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
  • Department of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Kanagawa, Japan.
  • Department of Head and Neck Surgery, Kanagawa Cancer Center, Kanagawa, Japan.
  • Department of Otorhinolaryngology, Head and Neck Surgery, Yokohama City University, Kanagawa, Japan.

Zitieren

APA

Fushimi, C., Okamoto, I., Matsuki, T., Okada, T., Ueda, Y., Takahashi, H., Sato, H., Kondo, T., Tokashiki, K., Hanyu, K., Ito, T., Kushihashi, Y., Masubuchi, T., Tada, Y., Omura, G. O., Yamashita, T., Oridate, N., & Tsukahara, K. (2026). Salvage Chemotherapy After Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. In Vivo, 40(6), 3648-3656. https://doi.org/10.21873/invivo.14503

Vancouver

Fushimi C, Okamoto I, Matsuki T, Okada T, Ueda Y, Takahashi H, et al. Salvage Chemotherapy After Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. In Vivo. 2026;40(6):3648-3656. doi:10.21873/invivo.14503

BibTeX
@article{Fushimi2026,
  author = {Fushimi, Chihiro and Okamoto, Isaku and Matsuki, Takashi and Okada, Takuro and Ueda, Yuri and Takahashi, Hideaki and Sato, Hiroki and Kondo, Takahito and Tokashiki, Kunihiko and Hanyu, Kenji and Ito, Tatsuya and Kushihashi, Yukiomi and Masubuchi, Tatsuo and Tada, Yuichiro and Omura, G O and Yamashita, Taku and Oridate, Nobuhiko and Tsukahara, Kiyoaki},
  title = {Salvage Chemotherapy After Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma},
  journal = {In Vivo},
  year = {2026},
  volume = {40},
  number = {6},
  pages = {3648--3656},
  doi = {10.21873/invivo.14503}
}
Kostenlos starten →